The Exchange has sought clarification from Valiant Laboratories Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE has asked Valiant Laboratories to explain why segment-wise revenue details were not submitted along with its financial results for the quarter ended 30 September 2025. This is a procedural compliance query under SEBI's Listing Regulations. The company's response is still awaited. The company has not been penalised, and no enforcement action has been mentioned.
This is a routine exchange clarification and not a punitive action. However, repeated non-compliance with disclosure norms can attract scrutiny and may affect investor confidence in the company's reporting practices.